U.S. patent application number 14/715262 was filed with the patent office on 2016-11-24 for systems and methods for recording evoked responses from neurostimulation.
The applicant listed for this patent is Pacesetter, Inc.. Invention is credited to Gene A. Bornzin, Edward Karst, Alexander Kent.
Application Number | 20160339251 14/715262 |
Document ID | / |
Family ID | 57324119 |
Filed Date | 2016-11-24 |
United States Patent
Application |
20160339251 |
Kind Code |
A1 |
Kent; Alexander ; et
al. |
November 24, 2016 |
SYSTEMS AND METHODS FOR RECORDING EVOKED RESPONSES FROM
NEUROSTIMULATION
Abstract
Systems and methods for closed loop spinal cord stimulation are
provided. The systems and methods position a first electrode
proximate to a dorsal column. The first electrode is electrically
coupled to an implantable pulse generator (IPG). The systems and
methods further program the IPG to deliver excitation pulses to the
first electrode based on a stimulation level. The excitation pulses
are emitted from the first electrode. The systems and methods
further position a second electrode proximate to a dorsal root. The
second electrode is electrically coupled to the IPG. The systems
and methods further measure at the second electrode a first evoked
potential waveforms resulting from the excitation pulses.
Inventors: |
Kent; Alexander; (Mountain
View, CA) ; Karst; Edward; (Los Angeles, CA) ;
Bornzin; Gene A.; (Simi Valley, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Pacesetter, Inc. |
Sunnyvale |
CA |
US |
|
|
Family ID: |
57324119 |
Appl. No.: |
14/715262 |
Filed: |
May 18, 2015 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61B 5/04001 20130101;
A61B 5/7235 20130101; A61B 5/4836 20130101; A61B 5/4041 20130101;
A61N 1/0551 20130101; A61N 1/36139 20130101 |
International
Class: |
A61N 1/36 20060101
A61N001/36; A61N 1/05 20060101 A61N001/05 |
Claims
1. A method for closed loop spinal cord stimulation, the method
comprising: positioning a first electrode proximate to a dorsal
column, wherein the first electrode is electrically coupled to an
implantable pulse generator (IPG); programming the IPG to deliver
excitation pulses to the first electrode based on a stimulation
level, wherein the excitation pulses are emitted from the first
electrode; positioning a second electrode proximate to a dorsal
root (DR), wherein the second electrode is electrically coupled to
the IPG; and measuring, at the second electrode, a first evoked
potential waveform resulting from the excitation pulses.
2. The method of claim 1, wherein the first evoked potential
waveform is measured from the second electrode which is located at
a cell body of a dorsal root ganglia or a spinal nerve.
3. The method of claim 1, further comprising determining from a
morphology of the first evoked potential waveform activation of one
or more sensory fiber types.
4. The method of claim 3, wherein the one or more sensory fiber
types include at least a A.beta. sensory fiber, A.delta. sensory
fiber, or a C sensory fiber.
5. The method of claim 3, wherein the one or more sensory fiber
types are determined from peak latencies of the first evoked
potential waveform.
6. The method of claim 3, further comprising adjusting the
stimulation level based on the morphology of the first evoked
potential waveform.
7. The method of claim 6, wherein adjusting the stimulation level
changes at least one of an amplitude, polarity, pulse width, or a
frequency of the excitation pulses delivered by the IPG.
8. The method of claim 3, wherein the morphology of the first
evoked potential waveform includes at least one of a slope or a
peak of the first evoked potential waveform during a predetermined
time period.
9. The method of claim 8, wherein the predetermined time period
depends on when the excitation pulses are emitted from the first
electrode.
10. The method of claim 3, further comprising: adjusting the
stimulation level based on a testing procedure; and iteratively
repeating the measuring, determining, and adjusting operations
until a therapeutic window is defined.
11. The method of claim 10, wherein the therapeutic window is
defined based on activation of an A.delta. sensory fiber or a C
sensory fiber.
12. The method of claim 1, further comprising: positioning a third
electrode proximate to a second DR or a contralateral DR
corresponding to the DR, wherein the DR corresponds to a first
dermatome and the second DR corresponds to a second dermatome; and
measuring, at the third electrode, a second evoked potential
waveform resulting from the excitation pulses.
13. The method of claim 1, further comprising repositioning a lead
based on the morphology of the evoked potential waveform, wherein
the lead includes the first electrode, the positioning operation of
the first electrode corresponding to an intraoperative placement of
the lead.
14. A system for closed loop spinal cord stimulation comprising: an
implantable pulse generator (IPG) electrically coupled to a first
electrode, wherein the IPG is configured to deliver excitation
pulses to the first electrode based on a stimulation level; and
sensing circuitry of the IPG electrically coupled to a second
electrode positioned proximate to a dorsal root (DR), wherein the
sensing circuitry is configured to measure a first evoked potential
waveform at the second electrode resulting from the excitation
pulses.
15. The system of claim 14, further comprising a lead having the
first electrode and the second electrode, wherein the first lead is
coupled to the IPG.
16. The system of claim 14, further comprising: a first lead having
the first electrode, wherein the first lead is positioned proximate
to a dorsal column; and a second lead having the second electrode,
wherein the first lead and the second lead are coupled to the
IPG.
17. The system of claim 14, further comprising: a controller of the
IPG that include one or more processors, the controller configured
to determine from a morphology of the first evoked potential
waveform activation of one or more sensory fiber types.
18. The system of claim 17, wherein the controller is further
configured to adjust the stimulation level based on the morphology
of the first evoked potential waveform.
19. The system of claim 17, wherein the controller is further
configured to adjust the stimulation level based on a testing
procedure to define a therapeutic window.
20. The method of claim 19, wherein the therapeutic window is
defined based on activation of an A.delta. sensory fiber or a C
sensory fiber.
Description
BACKGROUND OF THE INVENTION
[0001] Embodiments of the present disclosure generally relate to
neurostimulation (NS) systems, and more particularly to systems and
methods for recording evoked potentials resulting from NS for
closed loop spinal cord stimulation.
[0002] NS systems are devices that generate electrical pulses and
deliver the pulses to nerve tissue to treat a variety of disorders
via one or more electrodes. For example, SCS has been used to treat
chronic and intractable pain. Another example is deep brain
stimulation, which has been used to treat movement disorders such
as Parkinson's disease and affective disorders such as depression.
While a precise understanding of the interaction between the
applied electrical energy and the nervous tissue is not fully
appreciated, it is known that application of electrical pulses
depolarize neurons and generate propagating action potentials into
certain regions or areas of nerve tissue. The propagating action
potentials effectively mask certain types of physiological neural
activity, increase the production of neurotransmitters, or the
like. For example, applying electrical energy to the spinal cord
associated with regions of the body afflicted with chronic pain can
induce "paresthesia" (a subjective sensation of numbness or
tingling) in the afflicted bodily regions. Inducing this artificial
sensation replaces the feeling of pain in the body areas
effectively masking the transmission of non-acute pain sensations
to the brain.
[0003] During stimulation by the NS systems, evoked potentials are
emitted from the stimulated nerve tissue. The evoked potential
signals may be generated by neuronal transmembrane currents of
neurons activated following or in response to the NS. The
simultaneous activation of multiple neurons generates a signal of
sufficient amplitude for recording. The evoked potential signals
propagate within the population of sensory nerve fibers through
subsequent orthodromic or antidromic propagation from the
excitation site. It has been proposed that the NS system may
measure the evoked potential for a feedback mechanism to adjust the
NS.
[0004] However, the evoked potential signals are measured proximate
to the source of the NS, specifically, the electrodes of the NS
system near the dorsal column. Due to the proximity, the evoked
potential signal includes stimulation artifacts corresponding to
the NS emitted by the electrodes. Further, the evoked potential
signal measured at the dorsal column primarily corresponds to the
excitation of the sensory A.beta. fibers, since the A.delta. and C
fibers indicating pain travel in a different pathway located away
from the dorsal column. Moreover, the thickness of the
cerebrospinal fluid around the dorsal column reduces the evoked
potential signal. A need exists to overcome the shortcomings of
traditional recording locations of the evoked potential signal.
SUMMARY
[0005] In accordance with one embodiment, a method for closed loop
spinal cord stimulation is provided. The method includes
positioning a first electrode proximate to a dorsal column. The
first electrode is electrically coupled to an implantable pulse
generator (IPG). The method further includes programming the IPG to
deliver excitation pulses to the first electrode based on a
stimulation level. The excitation pulses are emitted from the first
electrode. The method includes positioning a second electrode
proximate to a dorsal root. The second electrode is electrically
coupled to the IPG. The method further measuring at the second
electrode a first evoked potential waveforms resulting from the
excitation pulses.
[0006] In an embodiment, a system for closed loop spinal cord
stimulation is provided. The system includes an implantable pulse
generator (IPG) electrically coupled to a first electrode
positioned proximate to a dorsal column. The IPG is configured to
deliver excitation pulses to the first electrodes based on a
stimulation level. The system also includes sensing circuitry of
the IPG of electrically coupled to a second electrode positioned
proximate to a dorsal root. The sensing circuitry is configured to
measure a first evoked potential waveform at the second electrode
resulting from the excitation pulses.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 is illustrates a neurostimulation system, according
to an embodiment of the present disclosure.
[0008] FIG. 2 is a flowchart of a method for closed loop spinal
cord stimulation, according to an embodiment of the present
disclosure
[0009] FIG. 3 illustrates a lead placement for spinal cord
stimulation of a patient, according to an embodiment of the present
disclosure
[0010] FIG. 4 illustrates a placement of a first lead and a second
lead for spinal cord stimulation of a patient, according to an
embodiment of the present disclosure.
[0011] FIG. 5 illustrates a graphical representation of excitation
pulses delivered to an electrode based on a spinal cord stimulation
program, according to an embodiment of the present disclosure.
[0012] FIG. 6 illustrates an alternative view of the placement
shown in FIG. 4.
[0013] FIG. 7 illustrates a graphical representation of electrical
potential measurements at an electrode, in accordance with an
embodiment.
[0014] FIG. 8 illustrates graphical representations of electrical
potential measurements at a first and second electrode, in
accordance with an embodiment.
[0015] FIG. 9a is a graphical representation of excitation pulses
having an increased amplitude relative to the excitation pulses in
FIG. 5.
[0016] FIG. 9b is a graphical representation of excitation pulses
having an increased frequency relative to the excitation pulse in
FIG. 5.
[0017] FIG. 9c is a graphical representation of excitation pulses
having an increased pulse width relative to the spinal cord
stimulation pulses in FIG. 5.
[0018] FIG. 10 illustrates a graphical representation of evoked
potential waveforms, in accordance with an embodiment.
[0019] FIG. 11 is a graphical representation of a series of
excitation pulses according to a testing procedure, according to an
embodiment of the present disclosure.
[0020] FIG. 12 is a graphical representation of evoked potential
waveforms, according to an embodiment of the present
disclosure.
[0021] FIG. 13 is a flowchart of a method for defining a
therapeutic window, in accordance with an embodiment.
[0022] FIG. 14 illustrates a schematic block diagram of an external
device, in accordance with an embodiment.
DETAILED DESCRIPTION
[0023] While multiple embodiments are described, still other
embodiments of the described subject matter will become apparent to
those skilled in the art from the following detailed description
and drawings, which show and describe illustrative embodiments of
disclosed inventive subject matter. As will be realized, the
inventive subject matter is capable of modifications in various
aspects, all without departing from the spirit and scope of the
described subject matter. Accordingly, the drawings and detailed
description are to be regarded as illustrative in nature and not
restrictive.
[0024] Various embodiments described herein include a method and/or
system for a closed loop spinal cord stimulation based on a novel
approach for recording evoked potential waveforms at or proximate
to the dorsal root (DR). For example, the evoked potential
waveforms may be recorded from the cell bodies of the dorsal root
ganglion (DRG), spinal nerve, or the like. The recorded evoked
potential waveforms may include neural activity of the A.beta.
sensory fibers carrying non-painful sensory information to the
spinal cord, and A.delta. and C sensory fibers carrying information
about painful stimuli. The activation of the sensory fibers may
correspond to one or more characteristics of the morphology of the
recorded evoked potential waveform.
[0025] In various embodiments the recorded evoked potential
waveform may be used to adjust the NS parameters to maintain
sufficient activation of the appropriate types of neural elements.
For example, based on the morphology of the evoked potential
waveform, the NS parameters may be adjusted to increase an
amplitude corresponding to the activation of the A.beta. sensory
fibers. Optionally, based on the morphology of the recorded evoked
potential appropriate stimulation parameter ranges (i.e. minimum
and maximum stimulation amplitude) may be determined corresponding
to a therapeutic window. The recorded evoked potential waveforms
may be recorded from contacts present on a stimulation lead,
including a DRG lead or percutaneous lead with tip steered into the
dorsal root area, or on a plurality of leads. For example, a
stimulation lead proximate to the dorsal column (DC) and a DRG
lead.
[0026] A technical effect of the various embodiments herein improve
recording fidelity of the evoked potential waveform due to the
smaller intradural space of the DR between the lead and the
neurons, and the reduced motion of the recording lead with changes
in posture. A technical effect of the various embodiments herein
allow precise identification of areas affected by the NS based on
the recording of the evoked potential waveform at the DR that is
specific to a particular dermatome, which allow for precise
identification of the areas affect by the SCS. A technical effect
of the various embodiments herein allow patients to remain under
general anesthesia during intraoperative placement of a lead. A
technical effect of the various embodiments herein provides a means
to objectively quantify the effect of SCS on a patient rather than
relying on subjective descriptions from the patient.
[0027] FIG. 1 depicts an NS system 100 that generates electrical
pulses (e.g., excitation pulses) for application to tissue of a
patient according to one embodiment. For example, the NS system 100
may be adapted to stimulate spinal cord tissue, dorsal root, dorsal
root ganglion, peripheral nerve tissue, deep brain tissue, cortical
tissue, cardiac tissue, digestive tissue, pelvic floor tissue, or
any other suitable nerve tissue of interest within a patient's
body.
[0028] The NS system 100 includes an implantable pulse generator
(IPG) 150 that is adapted to generate electrical pulses for
application to tissue of a patient. The IPG 150 typically comprises
a metallic housing or can 159 that encloses a controller 151, pulse
generating circuitry 152, a charging coil 153, a battery 154, a
far-field and/or near field communication circuitry 155, battery
charging circuitry 156, switching circuitry 157, sensing circuitry
158, memory 161, and the like. The controller 151 typically
includes a microcontroller or other suitable processor for
controlling the various other components of the device. Software
code may be stored in memory 161 of the IPG 150 or integrated with
the controller 151 for execution by the microcontroller or
processor to control the various components of the device.
[0029] The IPG 150 may comprise a separate or an attached extension
component 170. If the extension component 170 is a separate
component, the extension component 170 may connect with a "header"
portion of the IPG 150 as is known in the art. If the extension
component 170 is integrated with the IPG 150, internal electrical
connections may be made through respective conductive components.
Within the IPG 150, electrical pulses are generated by the pulse
generating circuitry 152 and are provided to the switching
circuitry 157. The switching circuitry 157 connects to outputs of
the IPG 150. Electrical connectors (e.g., "Bal-Seal" connectors)
within the connector portion 171 of the extension component 170 or
within the IPG header may be employed to conduct various
stimulation pulses. The terminals of one or more leads 110 are
inserted within the connector portion 171 or within the IPG header
for electrical connection with respective connectors. Thereby, the
pulses originating from the IPG 150 are provided to the one or more
leads 110. The pulses are then conducted through the conductors of
the lead 110 and applied to tissue of a patient via electrodes
111a-d. Any suitable known or later developed design may be
employed for connector portion 171.
[0030] The electrodes 111a-d may be positioned along a horizontal
axis 102 of the lead 110, and are angularly positioned about the
horizontal axis 102 so the electrodes 111a-d do not overlap. The
electrodes 111a-d may be in the shape of a ring such that each
electrode 111a-d continuously covers the circumference of the
exterior surface of the lead 110. Each of the electrodes 111a-d are
separated by non-conducting rings 112, which electrically isolate
each electrode 111a-d from an adjacent electrode 111a-d. The
non-conducting rings 112 may include one or more insulative
materials and/or biocompatible materials to allow the lead 110 to
be implantable within the patient. Non-limiting examples of such
materials include polyimide, polyetheretherketone (PEEK),
polyethylene terephthalate (PET) film (also known as polyester or
Mylar), polytetrafluoroethylene (PTFE) (e.g., Teflon), or parylene
coating, polyether bloc amides, polyurethane. The electrodes 111a-d
may be configured to emit the pulses in an outward radial direction
proximate to or within a stimulation target. The electrodes 111a-d
may also be configured to acquire electrical potential measurements
(e.g., voltage, current) for the sensory circuit 158, such as
evoked potentials emitted from the stimulation target.
[0031] Optionally, the IPG 150 may have more than one lead 110
connected via the connector portion 171 of the extension component
170 or within the IPG header. For example, a DRG stimulator, a
steerable percutaneous lead, and/or the like. Additionally or
alternatively, the electrodes 111a-d of each lead 110 may be
configured separately to emit excitation pulses or measure the
evoked potential emitted from the stimulation target.
[0032] Additionally or alternatively, the electrodes 111a-d may be
in the shape of a split or non-continuous ring such that the pulse
may be directed in an outward radial direction adjacent to the
electrodes 111a-d. Examples of a fabrication process of the
electrodes 111a-d is disclosed in U.S. patent application Ser. No.
12/895,096, entitled, "METHOD OF FABRICATING STIMULATION LEAD FOR
APPLYING ELECTRICAL STIMULATION TO TISSUE OF A PATIENT," which is
expressly incorporated herein by reference.
[0033] It should be noted the electrodes 111a-d may be in various
other formations, for example, in a planar formation on a paddle
structure as disclosed in U.S. Provisional Application No.
61/791,288, entitled, "PADDLE LEADS FOR NEUROSTIMULATION AND METHOD
OF DELIVERYING THE SAME," which is expressly incorporated herein by
reference.
[0034] The lead 110 may comprise a lead body 172 of insulative
material about a plurality of conductors within the material that
extend from a proximal end of lead 110, proximate to the IPG 150,
to its distal end. The conductors electrically couple a plurality
of the electrodes 111a-d to a plurality of terminals (not shown) of
the lead 110. The terminals are adapted to receive electrical
pulses and the electrodes 111a-d are adapted to apply the pulses to
the stimulation target of the patient. Also, sensing of
physiological signals may occur through the electrodes 111a-d, the
conductors, and the terminals. It should be noted that although the
lead 110 is depicted with four electrodes 111a-d, the lead 110 may
include any suitable number of electrodes 111a-d (e.g., less than
four, more than four) as well as terminals, and internal
conductors. Additionally or alternatively, various sensors (e.g., a
position detector, a radiopaque fiducial) may be located near the
distal end of the lead 110 and electrically coupled to terminals
through conductors within the lead body 172.
[0035] Although not required for all embodiments, the lead body 172
of the lead 110 may be fabricated to flex and elongate upon
implantation or advancing within the tissue (e.g., nervous tissue)
of the patient towards the stimulation target and movements of the
patient during or after implantation. By fabricating the lead body
172, according to some embodiments, the lead body 172 or a portion
thereof is capable of elastic elongation under relatively low
stretching forces. Also, after removal of the stretching force, the
lead body 172 may be capable of resuming its original length and
profile. For example, the lead body may stretch 10%, 20%, 25%, 35%,
or even up or above to 50% at forces of about 0.5, 1.0, and/or 2.0
pounds of stretching force. Fabrication techniques and material
characteristics for "body compliant" leads are disclosed in greater
detail in U.S. Provisional Patent Application No. 60/788,518,
entitled "Lead Body Manufacturing," which is expressly incorporated
herein by reference.
[0036] For implementation of the components within the IPG 150, a
processor and associated charge control circuitry for an IPG is
described in U.S. Pat. No. 7,571,007, entitled "SYSTEMS AND METHODS
FOR USE IN PULSE GENERATION," which is expressly incorporated
herein by reference. Circuitry for recharging a rechargeable
battery (e.g., battery charging circuitry 156) of an IPG using
inductive coupling and external charging circuits are described in
U.S. Pat. No. 7,212,110, entitled "IMPLANTABLE DEVICE AND SYSTEM
FOR WIRELESS COMMUNICATION," which is expressly incorporated herein
by reference.
[0037] An example and discussion of "constant current" pulse
generating circuitry (e.g., pulse generating circuitry 152) is
provided in U.S. Patent Publication No. 2006/0170486 entitled
"PULSE GENERATOR HAVING AN EFFICIENT FRACTIONAL VOLTAGE CONVERTER
AND METHOD OF USE," which is expressly incorporated herein by
reference. One or multiple sets of such circuitry may be provided
within the IPG 150. Different pulses on different electrodes 111a-d
may be generated using a single set of the pulse generating
circuitry 152 using consecutively generated pulses according to a
"multi-stimset program" as is known in the art. Complex pulse
parameters may be employed such as those described in U.S. Pat. No.
7,228,179, entitled "Method and apparatus for providing complex
tissue stimulation patterns," and International Patent Publication
Number WO 2001/093953 A1, entitled "NEUROMODULATION THERAPY
SYSTEM," which are expressly incorporated herein by reference.
Alternatively, multiple sets of such circuitry may be employed to
provide pulse patterns (e.g., tonic stimulation waveform, burst
stimulation waveform) that include generated and delivered
stimulation pulses through various electrodes of one or more leads
111a-d as is also known in the art. Various sets of parameters may
define the pulse characteristics and pulse timing for the pulses
applied to the various electrodes 111a-d as is known in the art.
Although constant excitation pulse generating circuitry is
contemplated for some embodiments, any other suitable type of pulse
generating circuitry may be employed such as constant voltage pulse
generating circuitry.
[0038] The sensing circuitry 158 may measure an electric potential
(e.g., voltage, current) over time of proximate tissue, such as the
DRG or DR, through at least one of the electrodes 111 and
configured to measure the electrical potential. For example, the
sensing circuitry 158 may measure an evoked potential waveform from
the neurons of the DRG or DR resulting from the excitation pulses
emitted for the NS. The sensing circuitry 158 may include
amplifiers, filters, analog to digital converters, memory storage
devices, digital signal processors or the like. Optionally, the
sensing circuitry 158 may store the electric potential in the
memory 161.
[0039] An external device 160 may be implemented to charge/recharge
the battery 154 of the IPG 150 (although a separate recharging
device could alternatively be employed), to access the memory 161,
and to program the IPG 150 on the pulse specifications while
implanted within the patient. Although, in alternative embodiments
separate programmer devices may be employed for charging and/or
programming the NS system 100. The external device 160 may be a
processor-based system that possesses wireless communication
capabilities. Software may be stored within a non-transitory memory
of the external device 160, which may be executed by the processor
to control the various operations of the external device 160. A
"wand" 165 may be electrically connected to the external device 160
through suitable electrical connectors (not shown). The electrical
connectors may be electrically connected to a telemetry component
166 (e.g., inductor coil, RF transceiver) at the distal end of wand
165 through respective wires (not shown) allowing bi-directional
communication with the IPG 150.
[0040] The user may initiate communication with the IPG 150 by
placing the wand 165 proximate to the NS system 100. Preferably,
the placement of the wand 165 allows the telemetry system of the
wand 165 to be aligned with the far-field and/or near field
communication circuitry 155 of the IPG 150. The external device 160
preferably provides one or more user interfaces 168 (e.g., display,
touchscreen, keyboard, mouse, buttons, or the like) allowing the
user to operate the IPG 150. The external device 160 may be
controlled by the user (e.g., doctor, clinician) through the user
interface 168 allowing the user to interact with the IPG 150. The
user interface 168 may permit the user to move electrical
stimulation along and/or across one or more of the lead(s) 110
using different electrode 111a-d combinations, for example, as
described in U.S. Patent Application Publication No. 2009/0326608,
entitled "METHOD OF ELECTRICALLY STIMULATING TISSUE OF A PATIENT BY
SHIFTING A LOCUS OF STIMULATION AND SYSTEM EMPLOYING THE SAME,"
which is expressly incorporated herein by reference. Optionally,
the user interface 168 may permit the user to designate which
electrodes 111a-d are to stimulate (e.g., emit excitation pulses,
in an anode state, in a cathode state) the stimulation target, to
measure the evoked potential (e.g., connecting to the sensing
circuitry 158) resulting from the excitation pulses, remain
inactive (e.g., floating), or the like. Additionally or
alternatively, the external device 160 may access or download the
electrical measurements from the memory 161 acquired by the sensing
circuitry 158.
[0041] Also, the external device 160 may permit operation of the
IPG 150 according to one or more spinal cord stimulation (SCS)
programs or therapies to treat the patient. For example, the SCS
program corresponds to the SCS delivered and/or executed by the IPG
150. Each SCS program may include one or more sets of stimulation
parameters of the pulses including pulse amplitude, stimulation
level, pulse width, pulse frequency or inter-pulse period, pulse
repetition parameter (e.g., number of times for a given pulse to be
repeated for respective stimset during execution of program),
biphasic pulses, monophasic pulses, etc. The IPG 150 may modify its
internal parameters in response to the control signals from the
external device 160 to vary the stimulation characteristics of the
stimulation pulses transmitted through the lead 110 to the tissue
of the patient. NS systems, stimsets, and multi-stimset programs
are discussed in PCT Publication No. WO 01/93953, entitled
"NEUROMODULATION THERAPY SYSTEM," and U.S. Pat. No. 7,228,179,
entitled "METHOD AND APPARATUS FOR PROVIDING COMPLEX TISSUE
STIMULATION PATTERNS," which are expressly incorporated herein by
reference.
[0042] FIG. 2 is a flowchart of a method 200 for a closed loop
spinal cord stimulation based on recorded evoked potential
waveforms measured proximate to the DR. The method 200 may employ
structures or aspects of various embodiments (e.g., systems and/or
methods) discussed herein. In various embodiments, certain steps
(or operations) may be omitted or added, certain steps may be
combined, certain steps may be performed simultaneously, certain
steps may be performed concurrently, certain steps may be split
into multiple steps, certain steps may be performed in a different
order, or certain steps or series of steps may be re-performed in
an iterative fashion. Furthermore, it is noted that the following
is just one possible method of a closed loop signal determining
and/or adjusting one or more stimulation parameters based on a
measured evoked potential waveform. It should be noted, other
methods may be used, in accordance with embodiments herein.
[0043] One or more methods may (i) position a first electrode
proximate to a dorsal column, (ii) program the IPG to deliver
excitation pulses to the first electrode based on a stimulation
level, (iii) position a second electrode proximate to a DR, and
(iv) measure, at the second electrode, a first evoked potential
waveform resulting from the excitation pulses.
[0044] Beginning at 202, a first electrode (e.g., 302a) is
positioned proximate to a dorsal column (DC) 306. FIG. 3 is an
illustration of a lead placement 300, in accordance with an
embodiment. The lead 310 is configured to flex such that a first
portion 312 of the lead 310 may extend parallel to the DC 306 along
an axis 320, and a second portion 314 may extend along a DR 308
parallel to an axis 322.
[0045] The first portion 312 of the lead 310 may be positioned at a
target position within an epidural space of a patient so as to be
in close proximity to a nerve tissue of interest along the DC 306.
The lead 310 includes a plurality of electrodes that form a first
and second series of electrodes 302 and 303 overlaid on the surface
of the lead 310. The first series of electrodes 302 may be
proximate and/or adjacent to a dura layer 316 of the DC 306. For
example, the electrode 302a may be located immediately adjacent to
the DC 306, such as within 3 mm of the DC 306. In another example,
the electrode 302a may be no more than 10 mm from the DC 306. The
first series of electrodes 302 are electrically coupled to an IPG
350. The IPG 350 may be similar to and/or identical to the IPG 150
shown in FIG. 1.
[0046] The second series of electrodes 303 may be proximate to
and/or adjacent to the epidural space of the DR 308. For example,
the electrode 303a may be located immediately adjacent to the DR
308, such as within 3 mm of the DR 308. In another example, the
electrode 303a may be no more than 10 mm from the DR 308. The DR
308 may correspond to a particular or select dermatome to be
stimulated by the IPG 350 based on the SCS program. The second
series of electrodes 303 are electrically coupled to the sensing
circuitry of the IPG 350, which allow the IPG 350 to identify
whether the stimulation target (e.g., the select dermatome) is
affected by the excitation pulses. For example, the second series
of electrodes 303 may enable the lead 310 to have a multi-contact
array of multiple electrode pairs to detect propagation of the
evoked potentials generated by one or more sensory fibers in
response to the excitation pulses.
[0047] It should be noted that in other embodiments, the lead 310
may include a curved paddle structure having an array of electrodes
along a front surface of the lead such that a first portion of the
array of electrodes are proximate to the dura layer 316 near DC 306
and a second portion of the array of electrodes are proximate to
the DR 308.
[0048] Optionally, the IPG 350 may be coupled to a first lead 410
and/or a second lead 412. FIG. 4 illustrates a placement of the
first lead 410 and the second lead 412, in accordance with an
embodiment. The first lead 410 and the second lead 412 may be
coupled to the IPG 350, for example, by a connector portion (e.g.,
the connector portion 171 of FIG. 1)
[0049] The first lead 410 may be positioned at a target position
within an epidural space of a patient so as to be in close
proximity to a nerve tissue of interest along the DC 306 extending
along the axis 320. The first lead 410 may include the first series
of electrodes 302 that are electrically coupled to the IPG 350. The
second lead 412 may extend along the DR 308 parallel to the axis
322. The second lead 412 may include the second series of
electrodes 303 that are electrically coupled to the sensing
circuitry of the IPG 350.
[0050] In at least one embodiment, additional leads may be coupled
to the IPG 350. For example, an additional lead may extend along
another DR corresponding to a dermatome not intended to be
stimulated by IPG 350, based on the SCS program. Additionally or
alternatively, the additional lead may extend along another DR
corresponding to an additional dermatome intended to be stimulated
by the IPG 350 based on the SCS program.
[0051] Additionally or alternatively, in at least one embodiment
the IPG 350 may not be coupled to a lead (e.g., the first lead 410)
positioned proximate to the DC 306. For example, the IPG 350 may be
coupled to the second lead 412 and/or additional leads proximate to
the DR 308 or DRG.
[0052] At 204, program the IPG 150 to deliver excitation pulses to
the first electrode (e.g., 302a) based on a stimulation level. The
stimulation level may correspond to an amplitude, frequency, pulse
width, and/or the like of the excitation pulses. The stimulation
levels may be defined by the SCS program. For example, the IPG 350
may be programmed or receive the SCS program from an external
device (e.g., the external device 160). The SCS program may define
one or more stimulation levels that correspond to different
simulation waveforms formed by the excitation pulses, such as a
burst stimulation waveform, a tonic stimulation waveform, a
biphasic pulse, or the like which are emitted from at least one of
the first series of electrodes 302.
[0053] For example, the excitation pulses may be delivered by the
IPG 350 to the electrode 302a. The excitation pulses are emitted
from the electrode 302a in an outward direction towards a
stimulation target within the DC 306. The excitation pulses may be
repeatedly emitted by the electrode 302a based on the SCS
program.
[0054] Additionally or alternatively, the excitation pulses may be
emitted from the first series of electrodes 302 and/or the second
series of electrodes 303. For example, the excitation pulses may be
delivered by the IPG 350 to the electrode 303a. The excitation
pulses are emitted from the electrode 303a in an outward direction
towards a stimulation target, such as, the DR 308 and/or DRG. In
another example, the excitation pulses may be delivered by the IPG
350 to the electrodes 302a and 303a.
[0055] FIG. 5 illustrates a series of excitation pulses 506
delivered by the IPG 350 and emitted by one or more of the first
series of electrodes 302 (e.g., the electrode 302a) and/or one or
more of the second series of electrodes 303 (e.g., the electrode
303a) of FIGS. 3 and 4 at a predetermined amplitude (e.g., a
positive amplitude 512, a negative amplitude 510) and duration 514,
516 in accordance with an embodiment. A horizontal axis 502
represents time, and a vertical axis 504 may represent voltage,
electrical potential, or current. The excitation pulses 506 form a
stimulation waveform based on the SCS program, such as a tonic or
burst stimulation waveform.
[0056] It should be noted that in other embodiments the excitation
pulses 506 may form other stimulation waveforms (e.g., burst
stimulation waveform). It should be noted that although the
amplitudes 510 and 512 are shown being equal in magnitude, in
alternative embodiments the amplitudes 510 and 512 may not equal.
For example, the positive amplitude 512 may have a greater
amplitude than the negative amplitude 510.
[0057] It should be noted that although the durations 514 and 516
of the excitation pulses 506 are shown being equal in length (e.g.,
pulse width), in alternative embodiments the durations 514 and 516
may not be equal. For example, the duration 514 of the excitation
pulse 506 corresponding to the positive amplitude 512 may be longer
or shorter in length (e.g., pulse width) than the duration 516 of
the excitation pulse 506 corresponding to the negative amplitude
510.
[0058] At 206, a second electrode (e.g., 303a) is positioned
proximate to the DR 308. FIG. 6 is an alternative view of the lead
placement shown in FIG. 4. FIG. 6 illustrates an electrode 303a of
the lead 412 positioned proximate to the DR 308, or particularly,
to cell bodies (e.g., soma) of the DRG 602. The DR 308 is further
illustrated meeting with the ventral root 604 at a spinal nerve
606. The DR 308 contains afferent or sensory nerve fibers such as
the A.beta. sensory fiber, the A.delta. sensory fiber, and the C
sensory fiber that correspond to a select or particular dermatome
intended to be stimulated by the SCS program. The ventral root 604
contains efferent or motor nerve fibers. The spinal nerve 606,
which branches into the DR 308 and the ventral root 604, includes
both the afferent nerve fibers (e.g., A.beta. sensory fiber, the
A.delta. sensory fiber, the C sensory fiber) and efferent nerve
fibers (e.g., motor fibers).
[0059] The electrodes 303 may be positioned adjacent to the
epidural space of the DR 308, such that the intradural space is
between the DR 308 and the electrodes 303. The position of the
second series of electrodes 303 of the lead 412 enable one or more
of the electrodes 303 (e.g., the electrode 303a) to detect and/or
measure the evoked potentials generated by one or more of the
A.beta. sensory, A.delta. sensory, and/or C sensory fibers in
response to the excitation pulses 506 emitted from the electrode
302a. For example, the second series of electrodes 303 are
positioned along a travel path of the antidromic propagation of the
evoked potential generated by the one or more of the A.beta.
sensory, A.delta. sensory, and/or C sensory fibers. The travel path
may include the cell bodies of the DRG 308 to the spinal nerve 606
along the axon 608.
[0060] In various embodiments, the electrode 303a of the lead 412
may be positioned in other locations proximate to the DR 308 other
than the DRG 308 as shown in FIG. 6. For example, the electrode
303a may be positioned adjacent to the spinal nerve 606. In another
example, the electrode 303a may be positioned along the axon 608
between the spinal nerve 606 and the DRG 308. Additionally or
alternatively, the one or more of electrodes 303 may be positioned
at and/or proximate to the spinal nerve 606 to detect and/or
measure the evoked potentials generated by one or more of the
afferent nerve fibers concurrently or simultaneously with action
potentials generated by the efferent nerve fibers.
[0061] At 208, measure at the second electrode (e.g., 303a) an
evoked potential waveform 706 resulting from the excitation pulses
506. FIG. 7 illustrates a graphical representation 700 of
electrical potential measurements at the electrode 303a proximate
to the cell bodies of the DRG 602. A horizontal axis 704 represents
time, and a vertical axis 702 represents a voltage of sensed
electrical potentials measured at the electrode 303a. The
electrical potential measurements correspond to an electrical
potential (e.g., voltage) at the electrode 303a measured by the
sensing circuitry 158. The electrical potential measurements form
an evoked potential waveform 706 resulting from the excitation
pulses 506, which are measured by the sensing circuitry 158 at the
electrode 303a.
[0062] For example, during intraoperative placement or implantation
of the lead (e.g., the lead 310, the leads 410, 412), under general
anesthesia, the clinician may instruct the IPG 350 to emit
excitation pulses for intraoperative targeting of the lead. The IPG
350 may instruct the electrode 302a to emit the excitation pulses
506 towards neurons corresponding to a select dermatome (e.g., the
stimulation target) within the DC 306. The excitation pulses 506
may generate evoked potentials within the neurons along one or more
sensory fibers corresponding to the select dermatome. The evoked
potentials travel along the sensory nerve fibers during subsequent
antidromic propagation towards the electrode 303a positioned
proximate to the DR 308 corresponding to the select dermatome. The
electrical characteristics (e.g., voltage, current) of the evoked
potentials may adjust and/or change the electrical potential at
and/or proximate to the electrode 303a. The sensing circuitry 158,
electrically coupled to the electrode 303a, may measure and/or
detect the evoked potentials corresponding to the change in
electrical potential over time at the electrode 303a at a sampling
and/or acquisition frequency. The sampling frequency may correspond
to a number of electrical potential measurements the sensing
circuitry 158 may measure over time. The electrical potential
measurements or evoked potential recordings are shown plotted over
time in the graphical representation 700, forming the evoked
potential waveform 706.
[0063] Optionally, if the evoked potential waveform 706 is not
detected by the sensing circuitry 158, the clinician may adjust a
position of the lead (e.g., the lead 310, the leads 410, 412)
during the intraoperative placement procedure. For example, the
controller 151 may determine that when no evoked potential waveform
706 is detected (e.g., the morphology of the evoked potential
waveform 706 does not include any peaks or remains below a
threshold) and/or measured by the sensing circuitry 158, the
excitation pulses 506 are not stimulating neurons of the select
dermatome. The IPG 350 may transmit a message to the external
device 160 informing the clinician to adjust a position of the
corresponding lead emitting the excitation pulses 506 (e.g., the
first lead 410, the second lead 412).
[0064] Optionally, the sensing circuitry 158 may measure the evoked
potentials resulting from the excitation pulses 506 at one or more
of the electrodes 303 of the lead 412. Additionally or
alternatively, the sensing circuitry 158 may measure the evoked
potentials at additional leads coupled to the IPG 350 positioned at
an alternative DR or DRG.
[0065] During intraoperative targeting of the lead (e.g., the lead
310, the lead 412) the IPG 350 may compare the evoked potentials
measured by the sensing circuitry 158 to determine which dermatomes
are being stimulated by the excitation pulses 506. Multiple leads
positioned at corresponding dermatomes may allow the IPG 350 to
distinguish between the dermatomes affected by the excitation
pulses 506 while the patient is kept under general anesthesia. For
example, the IPG 350 may be electrically coupled to the lead 410,
412 and a third lead. The third lead may include one or more
electrodes proximate to a second DR corresponding to a second
dermatome (e.g., a higher or lower dermatome) different than the
select dermatome corresponding to the DR 308. The IPG 350 may
determine that evoked potentials detected from the third lead
corresponds to stimulation of the second dermatome and evoked
potentials detected from the lead 412 corresponds to stimulation of
the select dermatome.
[0066] At 210, determine from a morphology of the evoked potential
waveform 706 activation of one or more sensory fiber types. The
morphology may correspond to a peak amplitude, a number of peaks,
peak width, peak latency, descending and/or ascending slopes,
and/or the like of the evoked potential waveform 706. The
morphology of the evoked potential waveform 706 may be determined
by the controller 151 and/or the sensing circuitry 158, for
example, based on changes in subsequent electrical potential
measurements.
[0067] For example, the sensing circuitry 158 acquired a plurality
of electrical potential measurements (e.g., 708, 714) over time at
the electrode 303a. The plurality of electrical potential
measurements form the evoked potential waveform 706. The electrical
measurement 708 having a voltage value 712 was acquired at 710, and
the electrical measurement 714 having a voltage value 718 was
acquired at 716. The electrical measurement 714 was measured by the
sensor circuitry 158 subsequent to the electrical measurement 708.
The controller 151 may compare the time 710, 716 and voltage values
712 and 718 of the electrical measurements 708 and 714,
respectively, to determine a slope of the evoked potential waveform
706 between the electrical measurements 708 and 714. The slope
represents a ratio of the change in voltage values 712, 718 and the
change in time 710, 716.
[0068] The controller 151 may continually determine additional
slopes for the evoked potential waveform 706 between adjacent
electrical measurements (e.g., the electrical measurements 714 and
720, the electrical measurements 720 and 722, the electrical
measurements 722 and 724) during a predetermined time period 740.
The predetermined time period 740 may be a value stored on the
memory 161 corresponding to an amount of time the sensing circuitry
158 acquires electrical measurements at the electrode 303a.
[0069] Optionally, the predetermined time period 740 may depend on
when the excitation pulses 506 are emitted from the first electrode
(e.g., the electrode 302a of FIG. 3). For example, the start of the
predetermined time period 740 may be based on when the electrode
302a emits the excitation pulses 506 to the stimulation target.
[0070] Based on changes in the magnitude and/or direction of the
slopes the controller 151 may determine a number of peaks of the
evoked potential waveform 706 with a corresponding amplitude (e.g.,
750-754). For example, the controller 151 may determine a slope of
the evoked potential waveform 706 between the electrical
measurements 720 and 722 is negative, and a slope of the evoked
potential waveform 706 between the electrical measurements 722 and
724 is positive. Based on the change in magnitude of the slope from
negative to positive, the controller 151 may determine that a peak,
particularly a negative peak 726, occurs between the electrical
measurements 720 and 724.
[0071] An amplitude (e.g., 750-754) of the peak may correspond to
the extent of activation of different types of sensory fibers
(e.g., the A.beta. sensory, A.delta. sensory, and/or C sensory
fibers). For example, a patient may feel more paresthesia from
excitation pulses that result in an evoked potential generated by
the A.beta. sensory fiber with a high amplitude relative to
excitation pulses that result in an evoked potential with a lower
amplitude. The amplitudes 750-754 may be determined by the
controller 151 based on a peak value (e.g., apex, vertex of
intersections of adjacent slopes) of the negative peaks 726-730
with respect to a baseline 760 (e.g., common ground of the NS
system 100). The amplitudes 750-754 may be stored by the controller
151 on the memory 161. Optionally, the amplitudes 750-754 may be
transmitted to the external device 160 by the communication
circuitry 155.
[0072] It should be noted that in other embodiments, the negative
peaks 726-730 and/or the evoked potential waveform 706 may have an
opposite polarity than shown in FIG. 7. For example, the evoked
potential waveform 706 may have positive peaks.
[0073] The evoked potentials are generated by a population of
neurons of one or more sensory fiber types proximate to the
stimulation target. The evoked potentials travel away from the
stimulation target towards the first and second series of
electrodes 302 and 303. A latency of the evoked potentials is based
on an action potential propagation speed of the sensory fiber type,
which corresponds to the fiber size and myelination of the fiber.
For example, the A.beta. sensory fiber is larger than the A.delta.
sensory fiber and the C sensory fiber. Thus, an evoked potential
generated by the A.beta. sensory fiber may travel faster relative
to an evoked potential generated by the A.delta. sensory fiber
and/or unmyelinated C sensory fiber.
[0074] In another example, the A.delta. sensory fiber is larger
than the C sensory fiber. Thus, an evoked potential generated by
the A.delta. sensory fiber may travel faster relative to an evoked
potential generated by the C sensory fiber.
[0075] In connection with FIG. 8, when the evoked potentials
generated by the sensory fibers travel further from the stimulation
target, the peaks of the evoked potentials corresponding to each
sensory fiber further separate with respect to each other in time.
The separation or latency of the evoked potentials with respect to
each other may be used by the controller 151 to distinguish between
the evoked potentials generated by the sensory fibers corresponding
to activation of the sensory fibers.
[0076] FIG. 8 illustrates graphical representations of electrical
potential measurements at the electrode 302a and 303a. A horizontal
axis 804 represents time, and a vertical axis 802 represents a
voltage of sensed electrical potentials measured at the electrode
303a. The electrical potential measurements form an evoked
potential waveform 806, which is measured by the sensing circuitry
158 at the electrode 302a resulting from the excitation pulses.
[0077] For example, the electrode 302a emits excitation pulses
received from the IPG 350 towards neurons corresponding to the
stimulation target (e.g., one or more dermatomes) within the DC
306. The evoked potential waveform 806 includes a stimulation
induced artifact component 808. The component 808 is an electrical
artifact in the electrical measurements of the evoked potential
waveform 806 due to the excitation pulses 506 emitted by the
electrode 302a. Optionally, the controller 151 and/or sensing
circuitry 158 may filter out the component 808 by automatically
adjusting the gain concurrently when the excitation pulses 506 are
delivered to the electrode 302a or blanking the sensing amplifiers
of the sensing circuitry 158 by connecting the amplifiers to ground
during stimulation.
[0078] The excitation pulses 506 may generate evoked potentials
within the neurons. The evoked potentials travel along the afferent
nerve fibers of the A.beta. sensory fiber, the A.delta. sensory
fiber, and the C sensory fiber during subsequent orthodromic and
antidromic propagation towards the electrode 302a and 303a. The
evoked potentials may adjust and/or change the electrical potential
at and/or proximate to the electrodes 302a and 303a. Due to the
proximity of the electrode 302a to the stimulated target, for
example the DC 306, the evoked potentials may be measured at the
electrode 302a before the electrode 303a.
[0079] The sensing circuitry 158, electrically coupled to the
electrode 302a, may measure and/or detect the evoked potentials
corresponding to the change in electrical potential over time at
the electrodes 302a at the sampling and/or acquisition frequency.
The evoked potential waveform 806 includes a negative peak 826
corresponding to the activation of one or more sensory fibers. The
negative peak 826 may include multiple evoked potentials generated
by the sensor fibers. For example, the negative peak 826 may
include an amplitude corresponding to evoked potential generated by
the A.beta. sensory fiber, the A.delta. sensory fiber, and/or C
sensory fiber.
[0080] The evoked potentials travel along the corresponding sensory
fibers at different rates based on the action potential propagation
speed of the sensory fiber towards the electrode 303a, forming the
evoked potential waveform 706. The different rates of antidromic
propagation of the evoked potentials traversing along the sensory
fibers may result in differences in latency of the evoked
potentials arriving at the electrodes 303. The latency of the
evoked potentials are illustrated by three negative peaks 726-730
of the evoked potential waveform 706 that correspond to activation
of the sensory fibers. The controller 151 may assign a sensory
fiber corresponding to each negative peak 726-730 based on the peak
latency or when the negative peak 726-730 is measured and/or
detected by the sensing circuitry 158 at the electrode 303a.
[0081] For example, the controller 151 may use the peak latencies
of the evoked potential waveform 706, based on the peak latencies
of the negative peaks 726-730, to distinguish between the different
sensory fiber types. The negative peak 726 is measured by the
sensing circuitry 158 at 810, which is before the negative peaks
728-730. The controller 151 may determine since the negative peak
726 was measured prior to the remaining negative peaks 728-730
during the predetermined time interval 740 the negative peak 726
corresponds to the A.beta. sensory fiber. The negative peak 728,
measured at 812 and positioned between the negative peaks 726 and
730 may be determined by the controller 151 to correspond to the
A.delta. sensory fiber. The controller 151 may determine that the
negative peak 730 measured at 816 and subsequent to the negative
peaks 726-728 corresponds to the C sensory fiber.
[0082] It should be noted that the electrical potential
measurements, measured at the electrodes 303 may have a higher
fidelity than the electrical potential measurements measured at the
electrodes 302. For example, the intradural space between the DR
308, which contains the sensory fibers, and the electrodes 303 is
smaller than the intradural space between the DC 306 and the lead
410 and/or the portion 312 position. The intradural space further
has less cerebral spinal fluid between the electrodes 303 and the
DR 308 relative to the intradural space separating the electrodes
302 from the DC 306. The cerebral spinal fluid may affect the
electrical characteristics of the evoked potentials generated by
the sensory fibers prior to being measured by the electrodes 302,
303. For example, the electrical currents generated by the evoked
potentials may be dispersed within the cerebral spinal fluid and
reduce the electrical potential of the evoked potential. By
positioning the electrodes 303 closer to the sensory fibers, the
effect of the cerebral spinal fluid on the electrical potential
measurements of the evoked potentials are reduced relative to the
electrodes 302; increasing the fidelity of the electrical potential
measurements measured at the electrodes 303 relative to the
electrical potential measurements measured at the electrodes
302.
[0083] Additionally, when the patient changes position, the lead
410 or the portion 312 of the lead 310 may move and/or change
position relative to the DC 306. Changes in position of the
electrodes 302 may alter which dermatome and/or combination of
dermatomes the electrical potential measurements correspond to,
reducing the fidelity of the electrical potential measurements
acquired at the electrodes 302. The position of electrodes 303 near
the DR is not as affected by patient changes in position relative
to the position of the lead 410 or the portion of the lead 310,
reducing the effects of changing a posture of the patient on the
electrical potential measurements of the electrodes 303. For
example, during changes in patient posture the electrodes 303 may
have negligible to relatively little motion compared to the
electrodes 302 increasing the fidelity of the electrical potential
measurements at the electrodes 303 relative to the electrical
potential measurements at the electrode 302.
[0084] At 212, adjust the stimulation level based on the morphology
of the evoked potential waveform 706. The activation of the A.beta.
sensory fiber is associated with paresthesia and non-painful
information. Conversely, the activation of the A.delta. sensory
fiber and/or the C sensory fiber is associated with painful
stimuli. The controller 151 may adjust the stimulation level to
increase the activation of the A.beta. sensory fiber and/or to
decrease the activation of the A.delta. sensory fiber and/or the C
sensory fiber.
[0085] For example, the controller 151 may adjust at least one of
an amplitude, polarity, pulse width, or frequency corresponding to
the stimulation level of the excitation pulses 506 delivered by the
IPG 150. Additionally or alternatively, the controller 151 may
select a different electrode 302 and/or additional electrodes 302
for emitting the excitation pulses 506. Optionally, the controller
151 may receive a new stimulation level and/or adjust the
stimulation level based on instructions received by the external
device 160. For example, the external device 160 may instruct the
controller 151 to adjust the stimulation level by changing the
pattern of the excitation pulses 506 from a tonic stimulation
waveform to a burst stimulation waveform.
[0086] The morphology of the evoked potential may be altered due to
changes in patient posture or migration of the stimulation or
recording leads. Changes in evoked potential morphology can be used
to detect a variation in patient posture or lead location, and
adjust stimulation parameters accordingly.
[0087] FIGS. 9a-c are graphical representations of exemplary
excitation pulses 906a-c with an adjusted stimulation level
relative to the excitation pulses 506 of FIG. 5. A horizontal axis
912 represents time, and a vertical axis 908 may represent voltage
or an electrical potential. It should be noted that the stimulation
level may be adjusted in additional or alternative ways to what is
shown in FIGS. 9a-c. For example, adjusting the polarity of the
excitation pulses 506.
[0088] FIG. 9a illustrates SCS pulses 906a having an increased
amplitude 910 and 916 over the amplitudes 514 and 516 of the
excitation pulses 506. It should be noted that in other embodiments
the duration 514, the duration 516 and/or the number of the
excitation pulses 906a may be increased as well. It should be noted
that although the amplitudes 910 and 916 are shown being increased
in equal magnitude, alternative embodiments may not. For example,
the positive amplitude 910 may have a greater amplitude than the
negative amplitude 916.
[0089] FIG. 9b illustrates excitation pulses 906b having an
increased number of excitation pulses 906b relative to the
excitation pulses 506 over the same time period. For example, the
excitation pulses 906b may have a higher frequency relative to the
excitation pulses 506. It should be noted that in other embodiments
the duration 514, the duration 516, the amplitude 510 and/or the
amplitude 512 of the excitation pulses 906b may be increased as
well.
[0090] FIG. 9c illustrates excitation pulses 906c having an
increased duration 918 and 920 (e.g., pulse width) relative to the
duration 514 and 516 of the excitation pulses 506. It should be
noted that in other embodiments the amplitude 510 and 512 and/or
number of the excitation pulses 906c may be increased as well. It
should be noted that although the durations 918 and 920 are shown
being increased in equal magnitude, in alternative embodiments the
duration 918 and 920 may not have an equal magnitude. For example,
the duration 918 may be longer than the duration 920.
[0091] FIG. 10 illustrates a graphical illustration 1000 of the
evoked potential waveform 706 and an evoked potential waveform 1006
resulting from adjustments to the stimulation level. The controller
151 may determine from the morphology (e.g., peak amplitude,
ascending and/or descending slope, number of peaks) negative peaks
1026-1030 of the evoked potential waveform 1006 corresponding to
activation of the A.beta. sensory fiber, the A.delta. sensory
fiber, and the C sensory fiber, for example as described at 210.
The amplitudes 1050-1054 of the negative peaks 1026-1030 may be
changed relative to the amplitudes 750-754 of the evoked potential
waveform 706 based on the adjusted stimulation level.
[0092] The controller 151 may compare the amplitudes 1050-1054 with
the amplitudes 750-754 to determine whether to further adjust the
stimulation level. For example, the controller 151 may adjust the
stimulation level to reduce the amplitudes 1052-1054 corresponding
to the A.delta. sensory fiber, and the C sensory fiber.
[0093] Additionally or alternatively, the lead (e.g., the lead 310,
the lead 410, the lead 412) may be repositioned based on the
morphology of the evoked potential waveform. For example, if the
evoked potential waveform does not include any peaks and/or remains
below an activation threshold the controller 151 may determine that
the one or more electrodes (e.g., 302, 303) delivering the
excitation pulses 506 has shifted and no longer stimulates the
stimulation target.
[0094] In connection with FIGS. 11-13, optionally, the controller
151 may adjust the stimulation level to an adjusted stimulation
level based on a testing procedure to determine a therapeutic
window 1130 shown in FIG. 11. The therapeutic window 1130 may
correspond to a range of stimulation parameters (e.g., amplitude,
frequency, pulse width) of test excitation pulses 1116-1122 based
on activation of the A.beta. sensory fiber, the A.delta. sensory
fiber, and/or the C sensory fiber determined by the controller 151
from evoked potential recordings. For example, the therapeutic
window 1130 may correspond to a maximum amplitude that can be
applied by the electrodes 302 without activating the A.delta.
sensory fiber and/or the C sensory fiber that are associated with
pain. Additionally or alternatively, the range of stimulation
parameters within the therapeutic window 1130 may result in
activation of the A.beta. sensory fiber and/or minimal or lower
activation of the A.delta. sensory fiber and/or the C sensory fiber
relative to other stimulation levels or parameters of excitation
pulses outside the therapeutic window 1130.
[0095] FIG. 13 is a flowchart of a method 1300 for determining the
therapeutic window. The method 1300 may employ structures or
aspects of various embodiments (e.g., systems and/or methods)
discussed herein. In various embodiments, certain steps (or
operations) may be omitted or added, certain steps may be combined,
certain steps may be performed simultaneously, certain steps may be
performed concurrently, certain steps may be split into multiple
steps, certain steps may be performed in a different order, or
certain steps or series of steps may be re-performed in an
iterative fashion. It should be noted, other methods may be used,
in accordance with embodiments herein.
[0096] One or more methods may (i) adjust a stimulation level based
on a testing procedure, and (ii) iteratively repeat the measuring
(e.g., the method 200 at 208), determining (e.g., the method 200 at
210), and adjusting (e.g., the method 200 at 212) operations of the
method 200 until a therapeutic window is defined.
[0097] Beginning at 1302, test excitation pulses 1116 are defined
at an initial stimulation level based on a testing procedure. The
testing procedure may be stored on the memory 161 and/or received
by the external device 160. The testing procedure may include
algorithms and/or adjustment parameters for initial test excitation
pulses 1116 as well as for adjusting test excitation pulses
1116-1122 to determine the therapeutic window 1130 as described in
the method 1300. Optionally, the testing procedure may be based on
the SCS program to determine the stimulation levels for the
excitation pulses for SCS. In connection with FIG. 11, the testing
procedure may generate a series of test excitation pulses
1116-1120, such that each subsequent test excitation pulse
generates a different evoked potential waveform 1204-1210. For
example, the testing procedure may increment the stimulation level
of the test excitation pulses to activate one or more of the
sensory fibers.
[0098] FIG. 11 illustrates the series of test excitation pulses
1116-1122 delivered by the IPG 350 and emitted by at least one of
the electrodes 302 of FIG. 3. A horizontal axis 1114 may represent
time, and a vertical axis 1102 may represent voltage or electrical
potential. The test excitation pulses 1116 may correspond to an
initial stimulation level having an amplitude of 1104.
[0099] At 1304, the test excitation pulses 1116 are delivered to
the DC 306. For example, the IPG 350 may deliver the test
excitation pulses 1116 to one or more of the electrodes 302 similar
to and/or the same as the deliver operation at 204. It should be
noted that although the test excitation pulses 1116-1122 are shown
having a tonic or biphasic waveform, in other embodiments the one
or more excitation pulses 1116-1122 may be a burst waveform, or the
like.
[0100] Additionally or alternatively, the test excitation pulses
1116 may be delivered to the DR 308, the DRG 602 (FIG. 6), or the
spinal nerve 606. For example, the IPG 350 may deliver the test
excitation pulses 1116 to one or more of the electrodes 303.
[0101] At 1306, one or more of the evoked potential waveforms
1204-1210 are measured at the DR. FIG. 12 is a graphical
representation 1200 of evoked potential waveforms 1204-1210
generated by the A.beta. sensory fiber, the A.delta. sensory fiber,
and/or the C sensory fiber in response to the test excitation
pulses 1116-1122. A horizontal axis 1222 represents time, and a
vertical axis 1220 may represent voltage or electrical potential.
The evoked potential waveform 1204 corresponds to the excitation
pulses 1116, the evoked potential waveform 1206 corresponds to the
excitation pulses 1118, the evoked potential waveform 1208
corresponds to the excitation pulses 1120, and the evoked potential
waveform 1210 corresponds to the excitation pulses 1122. The evoked
potential waveforms 1204-1210 are shown aligned at negative peaks
1230-1236 of the evoked potential waveforms 1204-1210. The evoked
potential waveforms 1204-1210 may be measured by the sensing
circuitry 158 at one or more electrodes 303 proximate to the DR
308, for example, as described at 208 of FIG. 2.
[0102] At 1308, determine whether the A.beta. sensory fiber is
activated. For example, the controller 151 may determine activation
of the A.beta. sensory fiber based on the morphology of the
measured evoked potential waveform 1204-1210 as described at 210.
For example, the controller 151 may determine slopes of the evoked
potential waveform 1204 between electrical potential measurements.
The controller 151 may identify a negative peak 1230 based on the
direction of the slopes, such as ascending, descending, and/or
approximately zero or flat. For example, the controller 151 may
identify a location of the negative peak 1230 based on adjacent
descending and ascending slopes.
[0103] Optionally, the controller 151 may compare the magnitude of
the slopes with a predetermined value to determine whether the
direction of the slope is ascending, descending, and/or
approximately zero or flat. For example, a magnitude of the slope
below the predetermined value may be determined by the controller
151 to be approximately flat. Reducing the chances of the
controller 151 determining false negative peaks from slight and/or
minimal changes in electrical potential measurements due to noise,
interference, and/or the like.
[0104] Additionally or alternatively, the controller 151 may
determine an amplitude of the negative peak 1230 by comparing a
peak value (e.g., apex, a vertex or intersection of adjacent slopes
of the negative peak 1230 with respect to a baseline 1250 (e.g.,
common ground of the NS system 100). The controller 151 may compare
the amplitude with a predetermined value to determine whether the
change in magnitude of adjacent slopes correspond to a negative
peak. For example, when the amplitude is below the predetermined
value the controller 151 may determine that adjacent slopes having
contrasting magnitudes do not form a negative peak. In another
example, when the amplitude is above the predetermined value the
controller 151 may determine that the adjacent slopes correspond to
a negative peak.
[0105] Based on a location of the negative peak 1230, the
controller 151 may determine whether the negative peak 1230
corresponds to activation of an A.beta. sensory fiber. For example,
since the A.beta. sensory fiber is more conductive than the
alternative sensory fibers, such as the A.delta. sensory fiber
and/or the C sensory fiber, the A.beta. sensory fiber may be
detected by the sensing circuitry 158 before a negative peak
corresponding to activation of the alternative sensory fibers.
Additionally or alternatively, the controller 151 may determine
that a negative peak occurring within a predetermined time 1224,
such as 1 ms, after the delivery of the test excitation pulses 1116
corresponds to the A.beta. sensory fiber.
[0106] If the A.beta. sensory fiber is not activated, then at 1312,
increment the stimulation level of the test excitation pulses 1116
at a constant rate based on the testing procedure. The testing
procedure may instruct the controller 151 to increment the
stimulation level by increasing at least one of the amplitude 1104,
the pulse width, and/or the frequency of the test excitation pulses
1116 at the constant rate (e.g., 1%, 2%, 5%, 10%) to form
subsequent test excitation pulses, such as the test excitation
pulses 1118. Additionally or alternatively, the testing procedure
may adjust the rate incremented by the controller 151 based on the
stimulation level. For example, the testing procedure may increase
the stimulation level at a higher rate for stimulation levels below
a threshold relative to stimulation levels above the threshold.
[0107] Optionally, the testing procedure may implement a pseudo
random adjustment pattern. For example, the testing procedure may
increment the stimulation level based on a pseudo random adjustment
corresponding to at least one of the amplitude 1104, the pulse
width, and/or the frequency of the test excitation pulses 1116 to
generate subsequent test excitation pulses 1118-1122. The increment
may be pseudo random such that adjustments to the stimulation level
between adjacent excitation pulses 1116-1122 may be different
relative to previous and/or subsequent adjustments to excitation
pulses 1116-1122.
[0108] Additionally or alternatively, the lead (e.g., the lead 310,
the lead 410, the lead 412) may be repositioned based on the
morphology of the evoked potential waveform. For example, if the
measured evoked potential does not include any peaks and/or remains
below an activation threshold the controller 151 may determine that
the one or more electrodes (e.g., 302, 303) delivering the
excitation pulses 1116 has shifted and no longer stimulates the
stimulation target.
[0109] If the A.beta. sensory fiber is activated, then at 1310,
determine whether the A.delta. sensory fiber and/or the C sensory
fiber is activated. The controller 151 may determine activation of
the A.delta. sensory fiber and/or the C sensory fiber based on the
morphology of the measured evoked potential waveform 1204-1210 as
described at 210 of FIG. 2. For example, the controller 151 may
determine slopes of the evoked potential waveform 1210 between
electrical potential measurements or evoked potential recordings.
The controller 151 may identify negative peaks 1240 and 1242 based
on the direction of the slopes, such as ascending, descending,
and/or zero.
[0110] Based on a location of the negative peaks 1240, 1242, the
controller 151 may determine whether the negative peaks 1240, 1242
correspond to activation of the A.delta. sensory fiber and/or the C
sensory fiber. For example, since the A.beta. sensory fiber has a
faster action potential propagation speed than the A.delta. sensory
fiber and/or the C sensory fiber, evoked potentials generated by
the A.delta. sensory fiber and/or the C sensory fiber may be
detected by the sensing circuitry 158 after the negative peak 1236
corresponding to activation of the A.beta. sensory fiber. For
example, the controller 151 may determine that since the negative
peak 1240 occurs after the negative peak 1236, the negative peak
1240 corresponds to activation of the A.delta. sensory fiber.
Additionally or alternatively, the controller 151 may determine
that a negative peak occurring outside a predetermined time 1224,
such as 1 ms, after the delivery of the test excitation pulses
1116-1122 corresponds to the A.delta. sensory fiber and/or the C
sensory fiber.
[0111] Additionally or alternatively, the controller 151 may
determine an amplitude of one or more of the negative peaks 1240,
1242 by comparing peak values (e.g., apex, vertex of intersections
of adjacent slopes) of the negative peaks 1240, 1242 with respect
to a baseline 1250 (e.g., common ground of the NS system 100). The
controller 151 may compare one or both of the amplitudes with a
predetermined value to determine whether the change in magnitude of
adjacent slopes correspond to a negative peak and/or the pain
attributed to activation of the A.delta. sensory fiber and/or the C
sensory fiber is present. For example, when the amplitude of the
negative peaks are below the predetermined value the controller 151
may determine that the A.delta. sensory fiber and/or the C sensory
fiber is not activated. In another example, when the amplitude of
the negative peaks are above the predetermined value the controller
151 may determine that the A.delta. sensory fiber and/or the C
sensory fiber is activated.
[0112] If the A.delta. sensory fiber and/or the C sensory fiber is
not activated, then at 1314, the controller 151 may expand the
therapeutic window 1130 to include the stimulation level. For
example, the controller 151 may determine that the evoked potential
waveform 1210 does not include negative peaks corresponding to
activation of the A.delta. sensory fiber and/or the C sensory
fiber. The controller 151 may include the one or more parameters,
such as the amplitude 1108, pulse width, and/or the like
corresponding to the stimulation level of the test excitation
pulses 1120 resulting in the evoked potential waveform 1210 to the
therapeutic window 1130 stored on the memory 161.
[0113] In another example, the controller 151 may determine that
the negative peaks 1240 and 1242 corresponding to evoked potentials
generated by the A.delta. sensory fiber and/or the C sensory fiber
have amplitudes that are below the predetermined value. The
controller 151 may include the one or more parameters, such as the
amplitude 1110, pulse width and/or the like corresponding to the
stimulation level of the test excitation pulses 1122 to the
therapeutic window 1130 stored on the memory 161.
[0114] If the A.delta. sensory fiber and/or the C sensory fiber is
activated, then at 1316 the controller 151 may add the stimulation
level to define the therapeutic window 1130. The controller 151 may
define the therapeutic window 1130 from the range of stimulation
parameters based on the initial stimulation level to the
stimulation level resulting in activation of the A.delta. sensory
fiber and/or the C sensory fiber. For example, the controller 151
may define the therapeutic window 1130 from the amplitude 1104 of
the initial stimulation level of the test excitation pulses 1116 to
the amplitude 1110 of the stimulation level of the test excitation
pulses 1122.
[0115] Additionally or alternatively, if the A.delta. sensory fiber
and/or the C sensor is activated at 1310 the controller 151 may
reduce the stimulation level to determine a maximum stimulation
level resulting in minimal or no activation of the A.delta. sensory
fiber and/or the C sensory fiber relative to the stimulation level
resulting in activation of the A.delta. sensory fiber and/or the C
sensory fiber determined at 1310. For example, the controller 151
may determine that the test excitation pulses 1122 result in
activation of the A.delta. sensory fiber and/or the C sensory
fiber. The controller 151 may reduce one or more stimulation
parameters (e.g., the amplitude 1110, pulse width) corresponding to
the stimulation level of the test excitation pulses 1122.
[0116] For example, the controller 151 may reduce the stimulation
level at a point between the stimulation level of the test
excitation pulses 1120 and 1122. And the controller 151 may
iteratively adjust between one or more stimulation parameters that
correspond to a stimulation level between the stimulation levels of
the test excitation pulses 1120 and 1122 to determine a stimulation
level having a maximum stimulation parameter (e.g., amplitude,
pulse width) that is above the test excitation pulses 1120 and
below the test excitation pulses 1122 that does not result in
activation of the A.delta. sensory fiber and/or the C sensory
fiber.
[0117] Optionally, the therapeutic window 1130 may be based on one
or more stimulation levels that result in an amplitude (e.g., 750,
1050) corresponding to activation of the A.beta. sensory fiber
greater than a predetermined baseline. Additionally or
alternatively, the therapeutic window 1130 may be based on one or
more stimulation levels that result in an amplitude (e.g., 752-754,
1052-1054) corresponding to activation of the A.delta. sensory
fiber and/or the C sensory fiber less than a predetermined
threshold.
[0118] Optionally, the controller 151 may adjust the stimulation
level based on the morphology of an evoked potential waveform
measured at one or more electrodes of a third lead coupled to the
IPG 350. For example, the IPG 350 may be coupled to the lead 410,
412 and a third lead. The third lead may include one or more
electrodes proximate to a second DR corresponding to a second
dermatome (e.g., a higher or lower dermatome) different than the
select dermatome corresponding to the DR 308. Additionally or
alternatively, the third lead may be positioned at a contralateral
DR corresponding to the DR 308 (e.g., a contralateral side with
respect to the DR 308). The sensing circuitry 158 may measure the
evoked potential waveform from the one or more electrodes of the
third lead resulting from the excitation pulses 506. Based on the
evoked potential recordings from the one or more electrodes of the
third lead, the controller 151 may adjust the stimulation level of
the excitation pulses 506.
[0119] For example, the third lead is positioned proximate to a
second DR corresponding to a second dermatome not intended to be
stimulated based on the SCS program. The controller 151 may
determine activation of a sensory fiber of the second dermatome
based on electrical potential measurements measured at one or more
electrodes of the third lead. For example, the controller 151 may
determine activation of the sensory fiber, such as the A.beta.
sensory fiber, based on a morphology (e.g., negative peak) of an
evoked potential waveform formed from the electrical potential
measurements as described at 210 of FIG. 2.
[0120] The controller 151 may adjust or tune the excitation pulses
506. In various embodiments, the controller 151 may adjust the
excitation pulses 506 to maximize an amplitude (e.g., the amplitude
750 of FIG. 7) of a negative peak (e.g., the negative peak 726) of
an evoked potential waveform corresponding to an activation of a
sensory fiber of the select dermatome and/or to minimize the
amplitude of a negative peak of the evoked potential waveform
corresponding to activation of a sensory fiber of the second
dermatome. For example, the controller 151 may adjust the
stimulation level of the excitation pulses 506 and/or select
additional and/or alternative electrodes 302 to emit the excitation
pulses 506. The adjustments to the excitation pulses 506 by the
controller 151 may redirect the stimulation of the excitation
pulses 506 away from the second dermatome and/or toward the select
dermatome within the DC 306.
[0121] For example, the adjusted stimulation level of the
excitation pulses 506 may reduce an amplitude of a negative peak
(e.g., 726) of the evoked potential waveform measured at the one or
more electrodes of the third lead corresponding to activation of
the sensory fiber of the second dermatome. Additionally, the
adjusted stimulation level of the excitation pulses 506 may
increase an amplitude of a negative peak (e.g., 726) of the evoked
potential waveform generated by a sensory fiber of the select
dermatome. Additionally or alternatively, the controller 151 may
incrementally increase the stimulation level of the excitation
pulses 506 to increase the amplitude of the negative peak of the
evoked potential waveform generated by the sensory fiber of the
select dermatome.
[0122] FIG. 14 illustrates a functional block diagram of an
external device 1400, according to at least one embodiment, that is
operated in accordance with the processes described herein and to
interface with the NS system 100 as described herein. The external
device 1400 may be similar to and/or the same as the external
device 160. The external device 1400 may be a workstation, a
portable computer, a tablet computer, a PDA, a cell phone and the
like. The external device 1400 includes an internal bus 1401 that
may connect/interface with a Central Processing Unit ("CPU") 1402,
ROM 1404, RAM 1406, a hard drive 1408, a speaker 1410, a printer
1412, a CD-ROM drive 1414, a floppy drive 1416, a parallel I/O
circuit 1418, a serial I/O circuit 1420, the display 1422, a
touchscreen 1424, a standard keyboard 1426, custom keys 1428, and
an RF subsystem 1430. The internal bus 1401 is an address/data bus
that transfers information between the various components described
herein. The hard drive 1408 may store operational programs as well
as data, such as stimulation waveform templates and detection
thresholds.
[0123] The CPU 1402 typically includes a microprocessor, a
microcontroller, or equivalent control circuitry, designed
specifically to control interfacing with the external device 1400
and with the NS system 100. The CPU 1402 may include RAM or ROM
memory, logic and timing circuitry, state machine circuitry, and
I/O circuitry to interface with the NS system 100. The display 1422
(e.g., may be connected to the video display 1432). The display
1422 displays various information related to the processes
described herein. The touchscreen 1424 may display graphic
information relating to the NS system 100 (e.g., stimulation
levels, stimulation waveforms, evoked potential measurements) and
include a graphical user interface. The graphical user interface
may include graphical icons, scroll bars, buttons, and the like
which may receive or detect user or touch inputs 1434 for the
external device 1400 when selections are made by the user.
Optionally the touchscreen 1424 may be integrated with the display
1422. The keyboard 1426 (e.g., a typewriter keyboard 1436) allows
the user to enter data to the displayed fields, as well as
interface with the RF subsystem 1430. Furthermore, custom keys
1428, for example, may turn on/off the external device 1400. The
printer 1412 prints copies of reports 1440 for a physician to
review or to be placed in a patient file, and the speaker 1410
provides an audible warning (e.g., sounds and tones 1442) to the
user. The parallel I/O circuit 1418 interfaces with a parallel port
1444. The serial I/O circuit 1420 interfaces with a serial port
1446. The floppy drive 1416 accepts diskettes 1448. Optionally, the
serial I/O port may be coupled to a USB port or other interface
capable of communicating with a USB device such as a memory stick.
The CD-ROM drive 1414 accepts CD-ROMs 1450.
[0124] The RF subsystem 1430 includes a central processing unit
(CPU) 1452 in electrical communication with RF circuitry 1454,
which may communicate with both memory 1456 and an analog out
circuit 1458. The analog out circuit 1458 includes communication
circuits to communicate with analog outputs 1464. The external
device 1400 may wirelessly communicate with the NS system 100 using
a telemetry system. Additionally or alternatively, the external
device 1400 may wirelessly communicate with the NS system 100
utilize wireless protocols, such as Bluetooth, Bluetooth low
energy, WiFi, MICS, and the like. Alternatively, a hard-wired
connection may be used to connect the external device 1400 to the
NS system 100.
[0125] Optionally, the external device 1400 may transmit the
stimulation database request to the IPG 150. For example, the user
may instruct the external device 1400 to transmit a stimulation
database request from the graphical user interface on the
touchscreen 1424, the keyboard 1426, or the like. The NS system 100
receives the request via the communication circuitry 155 (e.g., the
RF subsystem 1430, RF circuitry 1454) and transmits the stimulation
database stored on the memory 161 to the external device 900.
[0126] The controller 151, the CPU 1402, and the CPU 1452 may
include any processor-based or microprocessor-based system
including systems using microcontrollers, reduced instruction set
computers (RISC), application specific integrated circuits (ASICs),
field-programmable gate arrays (FPGAs), logic circuits, and any
other circuit or processor capable of executing the functions
described herein. Additionally or alternatively, the controller
151, the CPU 1402, and the CPU 1452 may represent circuit modules
that may be implemented as hardware with associated instructions
(for example, software stored on a tangible and non-transitory
computer readable storage medium, such as a computer hard drive,
ROM, RAM, or the like) that perform the operations described
herein. The above examples are exemplary only, and are thus not
intended to limit in any way the definition and/or meaning of the
term "controller." The controller 151, the CPU 1402, and the CPU
1452 may execute a set of instructions that are stored in one or
more storage elements, in order to process data. The storage
elements may also store data or other information as desired or
needed. The storage element may be in the form of an information
source or a physical memory element within the controller 151, the
CPU 1402, and the CPU 1452. The set of instructions may include
various commands that instruct the controller 151, the CPU 1402,
and the CPU 1452 to perform specific operations such as the methods
and processes of the various embodiments of the subject matter
described herein. The set of instructions may be in the form of a
software program. The software may be in various forms such as
system software or application software. Further, the software may
be in the form of a collection of separate programs or modules, a
program module within a larger program or a portion of a program
module. The software also may include modular programming in the
form of object-oriented programming. The processing of input data
by the processing machine may be in response to user commands, or
in response to results of previous processing, or in response to a
request made by another processing machine.
[0127] It is to be understood that the subject matter described
herein is not limited in its application to the details of
construction and the arrangement of components set forth in the
description herein or illustrated in the drawings hereof. The
subject matter described herein is capable of other embodiments and
of being practiced or of being carried out in various ways. Also,
it is to be understood that the phraseology and terminology used
herein is for the purpose of description and should not be regarded
as limiting. The use of "including," "comprising," or "having" and
variations thereof herein is meant to encompass the items listed
thereafter and equivalents thereof as well as additional items.
[0128] It is to be understood that the above description is
intended to be illustrative, and not restrictive. For example, the
above-described embodiments (and/or aspects thereof) may be used in
combination with each other. In addition, many modifications may be
made to adapt a particular situation or material to the teachings
of the invention without departing from its scope. While the
dimensions, types of materials and coatings described herein are
intended to define the parameters of the invention, they are by no
means limiting and are exemplary embodiments. Many other
embodiments will be apparent to those of skill in the art upon
reviewing the above description. The scope of the invention should,
therefore, be determined with reference to the appended claims,
along with the full scope of equivalents to which such claims are
entitled. In the appended claims, the terms "including" and "in
which" are used as the plain-English equivalents of the respective
terms "comprising" and "wherein." Moreover, in the following
claims, the terms "first," "second," and "third," etc. are used
merely as labels, and are not intended to impose numerical
requirements on their objects. Further, the limitations of the
following claims are not written in means--plus-function format and
are not intended to be interpreted based on 35 U.S.C. .sctn.112(f),
unless and until such claim limitations expressly use the phrase
"means for" followed by a statement of function void of further
structure.
* * * * *